Anti-GOLPH2 Monoclonal Antibody for WB, IF/ICC, IHC-P, ELISA - Q8NBJ4

Core Product Specifications and Parameters

Biological Background: GOLPH2 Function and Localization

• Golgi membrane protein 1 (GOLM1, also known as GP73, GOLPH2, HEL46) is a type II transmembrane protein anchored in the cis-Golgi network membrane.
• The protein is post-translationally modified by glycosylation and phosphorylation, resulting in an apparent molecular weight of ~45 kDa.
• While its precise molecular function remains unclear, GOLPH2 is identified as a cellular response protein to viral infection.
• GOLPH2 is widely expressed in epithelial tissues, with highest levels in colon, prostate, trachea, and stomach, and lower expression in testis, muscle, and lymphoid organs.
• In the liver, basal expression is low in hepatocytes but constitutive in biliary epithelial cells; expression markedly increases upon HBV or HCV infection, but not in non-viral liver diseases.
• Upregulation of GOLPH2 in hepatocytes correlates with advanced liver disease and is notably strong in syncytial giant cells of adult giant-cell hepatitis.

Experimental Guidance and Technical Tips

• For Western blotting, expect a primary band at approximately 45 kDa; confirm specificity using positive controls such as HepG2 cells and negative controls like normal hepatocyte lysates.
• In IHC-P/IHC-F, evaluate various antigen retrieval conditions (e.g., citrate buffer pH 6.0 or EDTA pH 9.0) to optimize epitope exposure, as the immunogen spans a luminal region.
• For immunofluorescence, permeabilize cells with 0.1% Triton X-100 or saponin to allow antibody access to the Golgi compartment.
• Combine with markers of viral replication or fibrosis when investigating GOLPH2’s role in liver pathology.
• Leveraging the recombinant rabbit monoclonal format ensures lot-to-lot consistency for reproducible results across experiments.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio stands as a strategic partner for IVD manufacturers and research laboratories, offering streamlined sourcing of raw materials from concept to clinic. This anti-GOLPH2 antibody supports liver disease research, and CamelBio’s portfolio includes validated antibody pairs, bulk monoclonal/polyclonal antibodies, and ancillary reagents, with the capability to secure rare-target materials for specialized assay development.